MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

Search

Pulmatrix Inc

Закрыт

4.81 -1.23

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

4.76

Макс.

4.89

Ключевые показатели

By Trading Economics

Доход

259K

-1.5M

Рентабельность продаж

-60,266.667

Сотрудники

2

EBITDA

260K

-1.5M

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-3.1M

17M

Предыдущая цена открытия

6.04

Предыдущая цена закрытия

4.81

Pulmatrix Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

2 окт. 2025 г., 23:30 UTC

Популярные акции

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 окт. 2025 г., 21:21 UTC

Отчет

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 окт. 2025 г., 00:00 UTC

Приобретения, слияния, поглощения

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 окт. 2025 г., 23:40 UTC

Обсуждения рынка

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 окт. 2025 г., 23:39 UTC

Обсуждения рынка

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 окт. 2025 г., 23:29 UTC

Приобретения, слияния, поглощения

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 окт. 2025 г., 23:29 UTC

Приобретения, слияния, поглощения

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 окт. 2025 г., 23:29 UTC

Приобретения, слияния, поглощения

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 окт. 2025 г., 23:00 UTC

Обсуждения рынка

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 окт. 2025 г., 22:54 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Scales's JV Buyout Lauded by Bull -- Market Talk

2 окт. 2025 г., 22:54 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Global Forex and Fixed Income Roundup: Market Talk

2 окт. 2025 г., 22:46 UTC

Обсуждения рынка

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 окт. 2025 г., 22:46 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

2 окт. 2025 г., 21:17 UTC

Приобретения, слияния, поглощения

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 окт. 2025 г., 20:50 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Energy & Utilities Roundup: Market Talk

2 окт. 2025 г., 20:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

2 окт. 2025 г., 20:49 UTC

Приобретения, слияния, поглощения

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 окт. 2025 г., 20:00 UTC

Приобретения, слияния, поглощения

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 окт. 2025 г., 19:20 UTC

Обсуждения рынка

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 окт. 2025 г., 19:10 UTC

Обсуждения рынка

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 окт. 2025 г., 19:04 UTC

Обсуждения рынка

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 окт. 2025 г., 18:46 UTC

Приобретения, слияния, поглощения

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 окт. 2025 г., 18:46 UTC

Приобретения, слияния, поглощения

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 окт. 2025 г., 18:46 UTC

Приобретения, слияния, поглощения

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 окт. 2025 г., 18:45 UTC

Приобретения, слияния, поглощения

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 окт. 2025 г., 18:45 UTC

Приобретения, слияния, поглощения

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 окт. 2025 г., 18:44 UTC

Приобретения, слияния, поглощения

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 окт. 2025 г., 18:44 UTC

Приобретения, слияния, поглощения

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 окт. 2025 г., 18:44 UTC

Приобретения, слияния, поглощения

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 окт. 2025 г., 18:43 UTC

Приобретения, слияния, поглощения

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Сравнение c конкурентами

Изменение цены

Pulmatrix Inc Прогноз

Консенсус по рейтингу

By TipRanks

0 ratings

0

Покупка

0

Удержание

0

Продажа

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.
help-icon Live chat